Literature DB >> 2731973

Antibody secretion by human intestinal mononuclear cells from normal controls and inflammatory bowel disease patients.

R P MacDermott1, G S Nash, M H Nahm.   

Abstract

Inflammatory bowel disease (IBD) intestinal mononuclear cells (MNC) exhibit decreased spontaneous IgA secretion with an increased percentage of monomeric IgA and IgA subclass 1 in both ulcerative colitis and Crohn's disease patients. When compared with control intestinal MNC, a marked increase in spontaneous secretion of IgG is observed from IBD MNC. The greatest increase in spontaneous IgG secretion is seen with ulcerative colitis intestinal MNC, due to the secretion of large amounts of IgG subclass 1. Crohn's disease intestinal MNC have increased IgG subclass 2 secretion. Similar differences in IgG subclass concentrations also occur in the sera of active, untreated, IBD patients. Therefore, major alterations occur with regard to spontaneous antibody secretion of IgA and IgG subclasses in IBD. Because intestinal MNC comprise a unique immunologic compartment, it will be important to better understand the regulatory mechanisms, effector capabilities, and inducing antigens involved in intestinal IgA and IgG subclass secretion in IBD.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731973     DOI: 10.3109/08820138909112255

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  6 in total

Review 1.  Immunopathogenesis of IBD: current state of the art.

Authors:  Heitor S P de Souza; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

Review 2.  The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions.

Authors:  Stephen M Vindigni; Timothy L Zisman; David L Suskind; Christopher J Damman
Journal:  Therap Adv Gastroenterol       Date:  2016-04-19       Impact factor: 4.409

Review 3.  Pulmonary manifestations of Crohn's disease.

Authors:  De-Gan Lu; Xiao-Qing Ji; Xun Liu; Hong-Jia Li; Cai-Qing Zhang
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

4.  Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): the mucosal effect in situ.

Authors:  Y Z Almallah; S W Ewen; A El-Tahir; N A Mowat; P W Brunt; T S Sinclair; S D Heys; O Eremin
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

5.  Decreased mucosal IgA levels in ileum of patients with chronic ulcerative colitis.

Authors:  L Cicalese; R H Duerr; M A Nalesnik; P F Heeckt; K K Lee; W H Schraut
Journal:  Dig Dis Sci       Date:  1995-04       Impact factor: 3.199

6.  Crohn's Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab.

Authors:  Aasem Abu Shtaya; Shai Cohen; Yana Kogan; Michal Shteinberg; Ori Sagool
Journal:  Eur J Case Rep Intern Med       Date:  2021-02-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.